Timon Seeger1,2, Rajani Shrestha1,2, Chi Keung Lam1,2, Caressa Chen1,2, Wesley L McKeithan1,2, Edward Lau1,2, Alexa Wnorowski1,3, George McMullen4, Matthew Greenhaw1,4, Jaecheol Lee1,2, Angelos Oikonomopoulos1,2, Soah Lee1,2,3,5, Huaxiao Yang1,2, Mark Mercola1,2, Matthew Wheeler1,2, Euan A Ashley1,2, Fan Yang3, Ioannis Karakikes1, Joseph C Wu1,2,6. 1. Stanford Cardiovascular Institute (T.S., R.S., C.K.L., C.C., W.L.M., E.L., A.W., M.G, J.L., A.O., S.L., H.Y., M.M., M.W., E.A.A., I.K., J.C.W.), Stanford University School of Medicine, CA. 2. Department of Medicine, Division of Cardiology (T.S., R.S., C.K.L., C.C., W.L.M., E.L., J.L., A.O., S.L., H.Y., M.M., M.W., E.A.A., J.C.W.), Stanford University School of Medicine, CA. 3. Department of Bioengineering (A.W., S.L., F.Y.), Stanford University School of Medicine, CA. 4. Department of Cardiothoracic Surgery (G.M., M.G., I.K.), Stanford University School of Medicine, CA. 5. Department of Orthopedic Surgery (S.L.), Stanford University School of Medicine, CA. 6. Institute for Stem Cell Biology and Regenerative Medicine (J.C.W.) Stanford University School of Medicine, CA.
Abstract
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is frequently caused by mutations in myosin-binding protein C3 ( MYBPC3) resulting in a premature termination codon (PTC). The underlying mechanisms of how PTC mutations in MYBPC3 lead to the onset and progression of HCM are poorly understood. This study's aim was to investigate the molecular mechanisms underlying the pathogenesis of HCM associated with MYBPC3 PTC mutations by utilizing human isogenic induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). METHODS: Isogenic iPSC lines were generated from HCM patients harboring MYBPC3 PTC mutations (p.R943x; p.R1073P_Fsx4) using genome editing. Comprehensive phenotypic and transcriptome analyses were performed in the iPSC-CMs. RESULTS: We observed aberrant calcium handling properties with prolonged decay kinetics and elevated diastolic calcium levels in the absence of structural abnormalities or contracile dysfunction in HCM iPSC-CMs as compared to isogenic controls. The mRNA expression levels of MYBPC3 were significantly reduced in mutant iPSC-CMs, but the protein levels were comparable among isogenic iPSC-CMs, suggesting that haploinsufficiency of MYBPC3 does not contribute to the pathogenesis of HCM in vitro. Furthermore, truncated MYBPC3 peptides were not detected. At the molecular level, the nonsense-mediated decay pathway was activated, and a set of genes involved in major cardiac signaling pathways was dysregulated in HCM iPSC-CMs, indicating an HCM gene signature in vitro. Specific inhibition of the nonsense-mediated decay pathway in mutant iPSC-CMs resulted in reversal of the molecular phenotype and normalization of calcium-handling abnormalities. CONCLUSIONS: iPSC-CMs carrying MYBPC3 PTC mutations displayed aberrant calcium signaling and molecular dysregulations in the absence of significant haploinsufficiency of MYBPC3 protein. Here we provided the first evidence of the direct connection between the chronically activated nonsense-mediated decay pathway and HCM disease development.
BACKGROUND:Hypertrophic cardiomyopathy (HCM) is frequently caused by mutations in myosin-binding protein C3 ( MYBPC3) resulting in a premature termination codon (PTC). The underlying mechanisms of how PTC mutations in MYBPC3 lead to the onset and progression of HCM are poorly understood. This study's aim was to investigate the molecular mechanisms underlying the pathogenesis of HCM associated with MYBPC3 PTC mutations by utilizing humanisogenic induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). METHODS:Isogenic iPSC lines were generated from HCM patients harboring MYBPC3 PTC mutations (p.R943x; p.R1073P_Fsx4) using genome editing. Comprehensive phenotypic and transcriptome analyses were performed in the iPSC-CMs. RESULTS: We observed aberrant calcium handling properties with prolonged decay kinetics and elevated diastolic calcium levels in the absence of structural abnormalities or contracile dysfunction in HCM iPSC-CMs as compared to isogenic controls. The mRNA expression levels of MYBPC3 were significantly reduced in mutant iPSC-CMs, but the protein levels were comparable among isogenic iPSC-CMs, suggesting that haploinsufficiency of MYBPC3 does not contribute to the pathogenesis of HCM in vitro. Furthermore, truncated MYBPC3 peptides were not detected. At the molecular level, the nonsense-mediated decay pathway was activated, and a set of genes involved in major cardiac signaling pathways was dysregulated in HCM iPSC-CMs, indicating an HCM gene signature in vitro. Specific inhibition of the nonsense-mediated decay pathway in mutant iPSC-CMs resulted in reversal of the molecular phenotype and normalization of calcium-handling abnormalities. CONCLUSIONS: iPSC-CMs carrying MYBPC3 PTC mutations displayed aberrant calcium signaling and molecular dysregulations in the absence of significant haploinsufficiency of MYBPC3 protein. Here we provided the first evidence of the direct connection between the chronically activated nonsense-mediated decay pathway and HCM disease development.
Authors: Antonio Sarikas; Lucie Carrier; Carolus Schenke; Daniela Doll; Jeanne Flavigny; Katrin S Lindenberg; Thomas Eschenhagen; Oliver Zolk Journal: Cardiovasc Res Date: 2005-04-01 Impact factor: 10.787
Authors: Lucie Carrier; Ralph Knöll; Nicolas Vignier; Dagmar I Keller; Pedro Bausero; Bernard Prudhon; Richard Isnard; Marie-Lory Ambroisine; Marc Fiszman; John Ross; Ketty Schwartz; Kenneth R Chien Journal: Cardiovasc Res Date: 2004-08-01 Impact factor: 10.787
Authors: Sabine J van Dijk; Dennis Dooijes; Cris dos Remedios; Michelle Michels; Jos M J Lamers; Saul Winegrad; Saskia Schlossarek; Lucie Carrier; Folkert J ten Cate; Ger J M Stienen; Jolanda van der Velden Journal: Circulation Date: 2009-03-09 Impact factor: 29.690
Authors: Steven Marston; O'Neal Copeland; Adam Jacques; Karen Livesey; Victor Tsang; William J McKenna; Shapour Jalilzadeh; Sebastian Carballo; Charles Redwood; Hugh Watkins Journal: Circ Res Date: 2009-07-02 Impact factor: 17.367
Authors: Sabine J van Dijk; Nicky M Boontje; Martijn W Heymans; Folkert J Ten Cate; Michelle Michels; Cris Dos Remedios; Dennis Dooijes; Marjon A van Slegtenhorst; Jolanda van der Velden; Ger J M Stienen Journal: Pflugers Arch Date: 2013-11-02 Impact factor: 3.657
Authors: Matthew J Birket; Marcelo C Ribeiro; Georgios Kosmidis; Dorien Ward; Ana Rita Leitoguinho; Vera van de Pol; Cheryl Dambrot; Harsha D Devalla; Richard P Davis; Pier G Mastroberardino; Douwe E Atsma; Robert Passier; Christine L Mummery Journal: Cell Rep Date: 2015-10-17 Impact factor: 9.423
Authors: Adam S Helms; Vi T Tang; Thomas S O'Leary; Sabrina Friedline; Mick Wauchope; Akul Arora; Aaron H Wasserman; Eric D Smith; Lap Man Lee; Xiaoquan W Wen; Jordan A Shavit; Allen P Liu; Michael J Previs; Sharlene M Day Journal: JCI Insight Date: 2020-01-30
Authors: Chi Keung Lam; Lei Tian; Nadjet Belbachir; Alexa Wnorowski; Rajani Shrestha; Ning Ma; Tomoya Kitani; June-Wha Rhee; Joseph C Wu Journal: Circ Res Date: 2019-05-13 Impact factor: 17.367
Authors: Gary Gintant; Paul Burridge; Lior Gepstein; Sian Harding; Todd Herron; Charles Hong; José Jalife; Joseph C Wu Journal: Circ Res Date: 2019-09-19 Impact factor: 17.367
Authors: Mira Holliday; Emma S Singer; Samantha B Ross; Seakcheng Lim; Sean Lal; Jodie Ingles; Christopher Semsarian; Richard D Bagnall Journal: Circ Genom Precis Med Date: 2021-03-03